Cumberland Pharmaceuticals announced a $100 million strategic transaction with Apotex Inc., selling its portfolio of FDA-approved brands to focus on developing orphan drug candidates addressing unmet medical needs. The deal, pending shareholder approval, aims to unlock shareholder value and support Cumberland's transition to a development-stage biopharmaceutical company. Cumberland's pipeline includes promising clinical programs for ifetroban, targeting rare diseases like Duchenne muscular dystrophy, systemic sclerosis, and pulmonary fibrosis, with recent FDA Fast Track designation for DMD. The company reported $9.1 million in Q1 2026 revenue and a net loss of $3.3 million, reflecting its shift towards innovation and development.
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
XRP's supply held on centralized exchanges has dropped to its lowest level in seven years, indicating reduced near-term sell pressure as holders move tokens to self-custody wallets. Despite this positive supply-side signal, XRP's price remains weak, ...
Maple Finance's SYRUP token surged 14% following significant growth in assets under management, reaching $4.6 billion in H1 2026, an 81% increase year-on-year. The rise is driven by strong capital inflows, especially into syrupUSDG, a stablecoin prod...
